PF-03622905
| Code | Size | Price |
|---|
| TAR-T38461-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC 50 s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα , PKCβI , PKCβII , PKCγ , and PKC? , respectively. PF-03622905 shows high specificity for PKC over other protein kinases.
CAS:
1072100-15-2
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Stephan Grant, et al. Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model. Eur J Pharmacol. 2010 Feb 10;627(1-3):16-25.